EXCLUSIVE: Fauci’s Agency Scrambled to Answer Questions on Changing Remdesivir Trial Endpoint: Emails

Dr. Anthony Fauci, chief medical adviser to President Joe Biden and the director of the National Institute of Allergy and Infectious Diseases, prepares to testify before a Senate panel in Washington on Jan. 11, 2022. Greg Nash/Pool/AFP via Getty Images

Dr. Anthony Fauci and top officials at the agency he heads scrambled in April 2020 to answer questions about altering the endpoint in a trial testing the antiviral drug called remdesivir, newly obtained emails show.

The endpoint was changed in the middle of the trial from measuring the effectiveness against death and various forms of hospitalization on day 15 to time to recovery through day 29.